このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

HALO 試験: 緩和ケア患者の多動性せん妄におけるハロペリドールとオランザピンの比較。多施設ランダム化対照試験

2026年9月30日 更新者:Mervyn Koh Yong Hwang、Tan Tock Seng Hospital
  1. Background and Clinical Need:

    Delirium is common at the end of life and is challenging to control. There is a clinical need to study the benefits of commonly used drugs like Haloperidol and Olanzapine in the management of hyperactive delirium in advanced cancer or end-stage organ disease patients in a scientifically robust manner.

  2. Aims/Hypotheses:

    The investigators aim to study the effectiveness of Haloperidol compared with Olanzapine in the management of hyperactive delirium in advanced cancer or end-stage organ disease patients receiving palliative care. The investigators hypothesise that Olanzapine is as effective as Haloperidol in the control of hyperactive delirium.

  3. Methods:

    The investigators will conduct a pragmatic, multi-centre, (hospital, inpatient hospice, community hospital) open-label randomised-controlled trial comparing the use of Haloperidol versus Olanzapine in advanced cancer or end-stage organ disease patients with hyperactive delirium.

    The primary outcome is the change in Richmond Agitation and Sedation Scale (RASS) scores among patients in each treatment group at 8 hours post-drug administration.

    The secondary outcome is the control of hyperactive delirium at 24, 48 and 72 hours using either Haloperidol or Olanzapine.

    The mean doses of Haloperidol and Olanzapine used as well as the volume of rescue Midazolam required as well as side-effects of the study medications, survival after enrolment into study will also be studied.

  4. Significance to palliative care The results of this study will advance the knowledge of delirium management worldwide with regards to the efficacy of Haloperidol and Olanzapine in managing hyperactive delirium in patients with advanced cancer or end-stage organ disease.

Haloperidol is used traditionally in palliative care for managing delirium. However, as a conventional anti-psychotic, it does cause extra-pyramidal side-effects. Olanzapine, a newer atypical anti-psychotic with a more favourable side-effect profile is being used increasingly in the control of delirium. These 2 commonly used drugs have never been compared head to head in a randomised-controlled, multi-centre study.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

(A) Background & Clinical Need

Delirium is commonly encountered in palliative care with a prevalence of between 26-74% and rising to as high as 88% nearer the end of life (2). It negatively impacts patient care and leads to greater morbidity and mortality (3). There are 3 sub-types of delirium - hyperactive, mixed and hypoactive (4) with majority of well-designed studies in palliative care focusing on the management of delirium as a whole (5). However, recently published literature suggests that these delirium subtypes appear to have different trajectories and are also generally treated differently (6).

Overall, the management of delirium in palliative care remains controversial. Agar had shown in a randomised controlled trial that supportive care may be superior to the use of anti-psychotics, even though the patients in Agar's study were only 'mildly' delirious and the overall doses of anti-psychotics used was lower than compared to common practice (9). Other studies have shown the benefits of anti-psychotics like haloperidol, olanzapine and aripiprazole in the management of delirium (10,11).

Hui et al was the only study which looked at the management of hyperactive delirium in the palliative care setting (7). Patients with hyperactive delirium exhibit restlessness, agitation and even aggression towards their loved ones and to healthcare providers caring for them (8).

To date, there have not been any multi-centre, randomised-controlled trial which has addressed the effectiveness of oral Haloperidol vs Olanzapine in the management of hyperactive delirium in the palliative care setting.

(B) Specific Aims

The investigators aim to study the effectiveness of Olanzapine vs Haloperidol in the management of hyperactive delirium in patients with advanced cancer or end-stage organ disease in 3 different settings.

The primary outcome is the change in Richmond Agitation and Sedation Scale (RASS) scores among patients in each treatment group at 8 hours after the administration of Haloperidol or Olanzapine as measured using the Richmond Agitation and Sedation Scale (RASS).

The secondary outcome is the change in Richmond Agitation and Sedation Scale (RASS) score at 24, 48 and 72 hours with the use of either Haloperidol or Olanzapine required.

The mean doses of Haloperidol and Olanzapine used as well as the doses of rescue Midazolam required as well as side-effects of the study medications, survival after enrolment into study will also be studied.

(C) Methods

Study Design

The investigators aim to conduct a multi-centre, randomised-controlled, open-label trial (Acute Hospital Palliative Care Unit, Palliative Care Unit in Community Hospital and Inpatient Hospice) comparing the use of haloperidol vs olanzapine in a 1:1 ratio in advanced cancer or end-stage organ disease patients with hyperactive delirium. Patients will be followed up for 3 days (72 hours) with regards to the response to study medications as well as other factors and outcomes as described below. Mortality data will also be collected.

The study will be conducted in 3 different Palliative Care Centres in Singapore - 1. Tan Tock Seng Hospital Acute Palliative Care Unit, 2. Palliative Care Unit in St Andrews' Community Hospital and 3. Dover Park Hospice. This is to increase the pragmatic applicability and external validity in this study to different palliative care units in Singapore and internationally.

Informed consent will be taken from the patient's legal representative according to the HBR Act as the patients recruited will be delirious and therefore will not able to provide informed consent adequately.

研究の種類

介入

入学 (実際)

22

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Singapore、シンガポール、308436
        • Dover Park Hospice
      • Singapore、シンガポール、529895
        • St. Andrew's Community Hospital
    • Singapore
      • Singapore、Singapore、シンガポール、308433
        • Tan Tock Seng Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

21年~99年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Patients with advanced cancer or end-stage organ disease

  2. Age ≥ 21 years old

  3. Fulfil All Three Diagnosis of Delirium:

    • Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria for delirium
    • Memorial Delirium Assessment Scale (MDAS)©1996 >/= 13
    • Richmond Agitation-Sedation Scale (RASS) Score +1 to +3
  4. Able to consume medications orally

  5. Prognosis > 48 hrs (Clinician Estimate)

Exclusion Criteria:

  1. Parkinson's Disease or Vascular Parkinsonism
  2. Patient with dementia
  3. Chronic Schizophrenia on regular Anti-psychotic medications
  4. Taking any regular Benzodiazepines* or any Anti-psychotic** medications
  5. Known allergy to Haloperidol or Olanzapine
  6. History of Substance Abuse
  7. Known Prolonged corrected QT interval (QTc) Syndrome (In Patient's Medical History)
  8. Prognosis < 48 hours (Clinician's Estimate)
  9. Unable to consume oral medications
  10. Richmond Agitation and Sedation Scale (RASS) Score +4 (Too agitated and will require Parenteral Anti-psychotics and/or Benzodiazepines)
  11. Pregnancy * e.g. Lorazepam, Alprazolam, Clonazepam, Midazolam **e.g. Haloperidol, Risperidone, Quetiapine, Olanzapine

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Haloperidol Arm

Haldol 2mg/ml oral solution

Starting dose: 1mg

Maximum Dose within 24 hours: 6mg

Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Haloperidol has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN).

アクティブコンパレータ:Olanzapine Arm

Olanzapine Actavis 5mg orodispersible tablet

Starting dose: 2.5mg

Maximum Dose within 24 hours: 15mg

Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Olanzapine has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Richmond Agitation and Sedation Scale (RASS) score
時間枠:8 hours

The change in Richmond Agitation and Sedation Scale (RASS) score 8 hours after administration of either Haloperidol and Olanzapine. Minimum value is -5 which represents that the patient is in hypoactive delirium and is unarousable and maximum value is +4 with the higher score representing that the patient is in hyperactive delirium and is combative. The aim of the study is to reduce the hyperactive delirium to a score of 0 which represents patient is alert and calm.

8 hours

二次結果の測定

結果測定
メジャーの説明
時間枠
Comparing Patient and Family's concurrence on state of delirium with of the Diagnosis of Delirium from Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria for delirium.
時間枠:72 hours

There have not been any studies that looked at interviewing patients who are delirious about their acknowledgement and concurrence of their state of delirium. The investigators aim to interview patients by asking the patient 'Did you feel confused' and caregivers similarly by asking 'Do you feel that your loved one is Confused' as shown as an example below and compare this to the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria for delirium.

Please ask the Patient the following question "Do you feel that you are confused?"

  1. Yes/Sometimes
  2. No
  3. Not Sure/ Unable to answer Please ask the Family member or Caregiver the following question "Do you think the patient is confused?"

1) Yes/Sometimes 2) No 3) Not sure/ Unable to answer

72 hours
Mean dose used of Haloperidol and Olanzapine
時間枠:72 hours

Mean doses of Haloperidol and Olanzapine used at 8hours / D1 / D2 / D3 from the first time-point that the study medication is administered to the patients

72 hours
Mean Time to control of Hyperactive Delirium
時間枠:72 hours

Mean Time to control of Hyperactive Delirium

72 hours
Rescue Psychotropic (Mean Doses): Midazolam
時間枠:72 hours

Rescue Psychotropic (Mean Doses): Midazolam

72 hours
Side-effects of Study Medications
時間枠:72 hours

Side-effects of Study Medications

72 hours
Survival time in days
時間枠:72 hours

Survival time in days

72 hours
Edmonton Symptom Assessment Score revised (ESAS-r)
時間枠:1 hour

Edmonton Symptom Assessment Score revised (ESAS-r) - At the point of recruitment

Minimum value for the scale is 0 and maximum value for the scale is 10 with the higher value representing worse outcome.

1 hour
Memorial Delirium Assessment Score (MDAS)
時間枠:72 hours

Memorial Delirium Assessment Score (MDAS) - At the point of recruitment and after 72 hours

It is a scale comprising of 10 items with scores of 0-3 for each question. Add up the score for all 10 questions and scores with more than or equal to 13 point indicates delirium.

72 hours
Richmond Agitation and Sedation Scale (RASS) score
時間枠:72 hours

Richmond Agitation and Sedation Scale (RASS) score: 8hours / 24hours (Day 1) / 48 hours (Day 2) / 72 hours (Day 3)

Minimum value is -5 which represents that the patient is in hypoactive delirium and is unarousable and maximum value is +4 with the higher score representing that the patient is in hyperactive delirium and is combative. The aim of the study is to reduce the hyperactive delirium to a score of 0 which represents patient is alert and calm.

72 hours
Caregiver and Nurses Perception on the control of hyperactive delirium
時間枠:72 hours

Caregiver and Nurses Perception on the control of hyperactive delirium (5-point Likert Scale). Kindly refer to the example of the question below.

The patient is less agitated as compared to 72 hours ago? (Clinician/Nurse):

  1. - Strongly Disagree
  2. - Disagree
  3. - Neutral
  4. - Agree
  5. - Strongly Agree

The patient is less agitated as compared to 72 hours ago? (Family/Caregiver):

  1. - Strongly Disagree
  2. - Disagree
  3. - Neutral
  4. - Agree
  5. - Strongly Agree
72 hours

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Mervyn Koh、Tan Tock Seng Hospital

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年5月18日

一次修了 (実際)

2025年9月25日

研究の完了 (実際)

2025年9月25日

試験登録日

最初に提出

2021年3月30日

QC基準を満たした最初の提出物

2021年4月5日

最初の投稿 (実際)

2021年4月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年9月30日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • PalC-RG-20/P001

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

There are no plans to make individual participant data available to other researchers.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。